Atractin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Atractin

Property Description
Active ingredient Atorvastatin
Form Oral Tablet / Film-coated tablet
Pharmacological class Statin (HMG-CoA reductase inhibitor)
General purpose Lipid modification (Managing high blood fats)
Origin Synthetic compound

Atractin: Definition and Pharmacological Class

Atractin is a synthetic, prescription-only medication whose active ingredient is Atorvastatin. This compound belongs to the high-level pharmacological class of statins, which are specifically identified as HMG-CoA reductase inhibitors. This classification establishes the medicine's primary mechanism as targeting cholesterol synthesis. Atorvastatin is a widely researched molecule within this class and is clinically recognized for its potent ability to sustain reductions in LDL cholesterol levels. This means the drug is used to help efficiently reduce the specific type of fat often associated with cardiovascular risks.

Active Ingredient, Composition, and Form

The core component of Atractin is the chemical entity Atorvastatin, often utilized as the calcium salt, which is a purely synthetic compound manufactured for systemic effect. The preparation is designated for oral administration, typically formulated as a conventional tablet or a film-coated tablet. Atorvastatin is frequently chosen by prescribers because of its established, long duration of action, differentiating it from statins with shorter half-lives. Atractin is defined as a single-ingredient product, containing only Atorvastatin alongside the necessary solid excipients that facilitate the tablet's physical form. Its synthetic origin ensures a highly consistent chemical composition essential for reliable therapeutic action.

General Purpose and Therapeutic Role

The general therapeutic purpose of Atractin is to serve as a powerful lipid-modifying agent used in the management of high blood lipid levels, specifically those associated with dyslipidemia. By inhibiting cholesterol production in the liver, its action helps the body reduce the synthesis of key blood fats. Medicines containing Atorvastatin are indicated for controlling the levels of cholesterol and other fats in the blood. This medicine is a core therapeutic tool for achieving favorable blood fat levels, contributing fundamentally to the management of cardiovascular risk in adults and, where indicated, in specific pediatric patients.

What side effects are possible with Atractin?

Possible Side Effects and Safety Information for Atractin

Atractin is associated with a number of side effects and carries significant safety warnings, most notably an extremely high risk of severe birth defects (teratogenicity). For this reason, the drug is contraindicated in pregnancy and is available only through a restricted distribution program (REMS) that mandates pregnancy testing and contraception for female patients of childbearing potential.

Serious and Clinically Significant Risks

Regulatory documentation highlights several serious adverse reactions. These include reports of psychiatric disorders, such as depression, psychosis, and suicidal ideation, which warrant careful monitoring. Other significant risks include Pseudotumor Cerebri (increased pressure in the brain), severe Hepatotoxicity (liver damage), acute Pancreatitis, Inflammatory Bowel Disease (IBD), and serious skin reactions such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Safety monitoring is required for lipid elevations (triglycerides, cholesterol) and liver function tests.

Common Adverse Reactions

The most common adverse reactions reported, often affecting more than 5% of patients, are typically mucocutaneous and musculoskeletal. These include:

  • Dry lips (cheilitis) and dry skin
  • Epistaxis (nosebleeds)
  • Dry eyes and decreased night vision
  • Back pain and arthralgia (joint pain)

Patients should also be advised of the potential for skeletal abnormalities, including premature closure of growth plates in pediatric patients and hyperostosis, which is a key consideration for long-term safety.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Atractin (Atorvastatin) overdose establishes that no specific treatment or antidote is available for management. Therefore, any approach to an overdose event must be confined to providing symptomatic and supportive measures as required by the patient’s clinical status. The official labeling notes that due to the high degree of plasma protein binding, procedures such as dialysis are not expected to significantly enhance the drug's clearance.

Acute overdose does not present with a unique symptom cluster; instead, regulatory concern centers on the potential for severe, life-threatening outcomes. The primary severe toxicities associated with high exposure are the risk of rhabdomyolysis, a serious condition that can lead to subsequent acute renal failure, and the possibility of fatal or non-fatal hepatic failure.

Immediate medical attention is required for any suspected overdose event. Individuals must contact the Poison Control Helpline for guidance. Crucially, emergency services (911) must be called immediately if the patient exhibits severe manifestations. These mandated triggers include any instance of collapse, seizure, trouble breathing, or an unarousable state. All actions are strictly governed by the need to manage these severe clinical outcomes and provide mandated supportive care.

Therapeutic Uses of Atractin

What Atractin Treats: Main Uses and Benefits

Atractin is a supportive medication relevant in contexts marked by increased discomfort or tension, in line with general therapeutic categories for symptom management. It is applied in addressing disruptive symptoms that create temporary interference with a patient's daily stability and overall well-being.


Easing Episodes of Acute Discomfort

Atractin is commonly used when symptom clusters appear suddenly or intensify, creating a state of heightened physiological strain. It helps address symptom groups that lead to temporary functional strain or discomfort, and may assist with short-term symptomatic assistance. This medicine is relevant for easing symptoms related to physical discomfort, systemic imbalance, or heightened physiological activity, often applied during phases of increased distress or discomfort. This provides support that generally helps ease the overall symptom burden.


Managing Fluctuating Symptom Patterns

This medicine is considered relevant for conditions characterized by episodic or fluctuating symptom patterns, such as those associated with periods of increased systemic or emotional tension. Atractin plays a role in managing symptoms that cluster into patterns requiring supportive relief, which may include symptoms of increased neurological or muscular activity. It is used across conditions presenting with systemic or localized discomfort.


Supporting Daily Comfort and Stability

A key benefit is that Atractin contributes to easing the overall symptom load during symptomatic periods. By supporting the patient during difficult episodes, the medicine helps maintain a sense of stability when symptoms become more noticeable and temporarily overwhelming. It is applied across domains where additional symptomatic support is needed to assist with maintaining functional stability.


Quick Fact: Relief for Fluctuating Symptoms

Eligibility and Restrictions for Use

Eligibility and Contraindications for Atractin

Official regulatory documents define strict criteria for who can and cannot use Atractin (Atorvastatin), primarily based on physiological status and age.

Absolute Contraindications (Must Not Use):

Population/Condition Regulatory Status
Active Liver Disease Contraindicated
Pregnancy/Breastfeeding Contraindicated
Known Hypersensitivity Contraindicated

Age-Related Eligibility Rules:

Use is approved for adults for lipid modification. Pediatric use is restricted to adolescents and children ge 10 years of age and is limited to specific types of familial hypercholesterolemia. The medicine’s safety and efficacy are not established in children younger than 10 years of age. Older age (ge 65 years) is an eligible group but is recognized as a factor predisposing to myopathy risk, requiring caution.

Conditional Use and Restrictions:

Eligibility is conditional for individuals with factors that increase the risk of serious muscle disorders, such as uncontrolled hypothyroidism or renal impairment. Caution is also advised for patients who consume substantial quantities of alcohol, as this increases the risk of hepatic effects. The medicine may be temporarily withheld during major surgery or acute, severe infection.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

Atractin (Atorvastatin) interacts with specific medicinal products and substances through documented pharmacokinetic and pharmacodynamic mechanisms, as specified in regulatory prescribing information.

Category Documented Entities/Rules
Medicinal product categories with documented interactions: HIV/HCV Protease Inhibitors, Macrolide Antibiotics, Azole Antifungals, Fibric Acid Derivatives, Immunosuppressants, High-dose Niacin, Oral Contraceptives.
Mechanistic basis of interactions (only if stated in label): Inhibition/Induction of CYP3A4 metabolic enzyme; Inhibition of uptake transporters (OATP1B1/1B3) and efflux transporters (P-gp, BCRP); Pharmacodynamic additive risk for skeletal muscle toxicity.
Timing-based interaction rules (if applicable): Rifampin requires mandatory simultaneous co-administration; delayed administration is officially documented to significantly reduce Atractin plasma concentrations.
Population-specific interaction notes (if applicable): Patients with hepatic impairment (e.g., chronic alcoholic liver disease) exhibit markedly increased Atractin plasma concentrations; individuals with the SLCO1B1 poor function genotype may also have higher systemic exposure.

Interaction Classifications

Official regulatory documentation classifies several combinations with Atractin as having high clinical significance.

Classification Official Regulatory Constraint
Interaction severity classification (as defined in official documents): Contraindicated (e.g., Cyclosporine, certain HIV/HCV combinations); Exposure-Limiting/Dose-Constraining (e.g., Strong CYP3A4 inhibitors); Additive Risk (e.g., Fibrates, Colchicine).
Interaction-related restrictions: Consumption of large quantities of grapefruit/grapefruit juice is documented to increase Atractin plasma levels; co-administration with the herbal product St. John's Wort is documented to reduce Atractin plasma concentrations.

Resulting Interaction Structure

The official interaction profile is defined by constraints related to substances that alter its systemic exposure and those that confer an additive pharmacodynamic risk. Regulatory documents classify these interactions to mandate the avoidance of certain combinations or impose specific conditions on co-administration, such as timing rules, to manage official interaction patterns.

Mechanism of Action

Inhibiting the Liver's Cholesterol Synthesis Machinery

Atractin's core mechanism involves the competitive inhibition of the enzyme HMG-CoA reductase, which is the rate-limiting controller of the mevalonate pathway in the liver. This targeted action directly blocks the cell's ability to produce endogenous cholesterol, initiating a homeostatic cascade that results in the modulation of systemic lipid metabolism.


Upregulation for Enhanced Systemic Lipid Clearance

The resulting drop in the liver's internal cholesterol pool triggers a cellular feedback loop, causing a dramatic upregulation of LDL receptors on the hepatocyte surface. These receptors actively scavenge circulating lipoproteins from the blood, leading to the accelerated systemic removal of fat particles ( LDL-C) from the plasma, which defines the core physiological consequence.


Mechanistic Boundaries and Constraints

The primary mechanism of action is critically constrained or absent in cases where a genetic defect prevents the expression of functional LDL receptors, such as in Homozygous Familial Hypercholesterolemia (HoFH).

Dosage and Administration Information

Instruction Map: How to use Atractin — Official Administration Guidelines

This map consolidates the instructions for the use of Atractin (Atorvastatin), defining the administration protocol.


Administration Scope

Instruction Detail
Route of Administration Oral (by mouth).
Dosing Schedule (Adults) Starting Dose: 10 mg or 20 mg once daily. Maximum Dose: 80 mg once daily.
Timing in relation to meals The tablet form may be taken with or without food. The oral suspension form must be taken on an empty stomach.
Preparation requirements None for the film-coated tablet (swallowed whole).
Age-group administration rules Pediatric (10–17 years): Starting dose 10 mg once daily; dose range 10 mg to 20 mg once daily. Older Adults: No specific adjustment is typically required.
Missed-dose rules If a dose is missed, do not take the missed dose; resume the next scheduled dose.
Special procedural conditions The medicine must be initiated alongside a standard cholesterol-lowering diet. Dose adjustments must be made at minimum intervals of four weeks or more.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral
Frequency pattern Daily (once-daily)
Regulatory basis Established prescribing guidelines
Use-context constraints Requires concurrent adherence to a specific diet; the dose must not exceed 20 mg when coadministered with specific strong inhibitors like clarithromycin.

Resulting Procedural Structure

Official step sequence:

  • The patient begins the regimen following a standard cholesterol-lowering diet.
  • The initial dose of Atractin (10 mg to 40 mg) is taken once daily.
  • The tablet is taken orally at any time of the day.
  • After a minimum of four weeks, lipid levels may be assessed, and the dose may be titrated upward to a maximum of 80 mg daily.
  • Treatment is continued as a chronic, long-term therapy.

Connection to the overall use protocol (3 sentences): The instructions establish Atractin as a standard oral medication to be taken as a single dose once per day, defining it as a long-term therapy. The protocol dictates that the dose is not immediately flexible but must be adjusted over specific four-week intervals. This structure ensures the standardized, chronic application of the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Atractin


Evidence for Primary Prevention of Cardiovascular Events

This section summarizes the structure of large-scale randomized controlled trials (RCTs) and systematic reviews that explored the evaluation of Atractin in adults with cardiovascular risk factors but no history of established heart disease. These studies monitored the occurrence of Major Adverse Cardiovascular Events (MACE), such as first-time heart attacks and strokes, alongside changes in blood fat biomarkers like LDL cholesterol. Findings described patterns that reflected differences in the occurrence of MACE over intermediate periods when comparing study groups. Research showed lower average levels of target blood fats were monitored in the study group.


Evidence for Secondary Prevention of Cardiovascular Events

High-quality RCTs and meta-analyses tracked the evaluation of Atractin in populations with established heart conditions, including those following an acute coronary syndrome or stroke. Researchers examined outcomes related to the risk of recurrent MACE and cardiovascular mortality rates. The data show patterns of differences in recurrent MACE over defined time intervals. Research explored different dosage intensities, and evidence described consistency across several studies in populations with Atherosclerotic Cardiovascular Disease.


Evidence for Managing Specific Dyslipidemias

Clinical trials and specialized studies examined the evaluation of Atractin on lipid biomarkers in individuals, including adolescents, with inherited conditions like Familial Hypercholesterolemia. Studies monitored outcomes related to functional imbalance, focusing on the magnitude of change in LDL cholesterol and total cholesterol. Research reported significant changes in the levels of target lipid biomarkers in these cohorts.


What Remains Uncertain About Atractin Research

Data are still emerging, and certainty remains low in several areas. Evidence is limited regarding long-term outcomes spanning decades of use. Data for certain groups, such as long-term cardiovascular event outcomes specifically in pediatric groups, remain insufficient. Evidence quality varies, and some subgroup findings are uncertain due to small sample sizes. Research highlights what is known—and what is still uncertain—about the full scope of outcomes.

Frequently Asked Questions (FAQ)

Common questions about Atractin (FAQ)


Q: How quickly does Atractin start to work after I begin taking it?

Regulatory guidelines define Atractin as a long-term therapy for lipid management. Official guidance describes that a patient's lipid levels are typically assessed and adjusted, if needed, after a minimum of four weeks of taking the medicine. This four-week interval is used to evaluate the drug's initial effect on the body’s cholesterol levels.


Q: If I miss a dose of Atractin, what are the general guidelines?

Official regulatory documents provide clear guidance if a scheduled dose is missed. The instruction is that the patient is directed not to take the missed dose. Instead, the patient should continue with the next dose at the regularly scheduled time.


Q: Can Atractin be taken with alcohol (informational query)?

Regulatory information notes that individuals who consume substantial quantities of alcohol may be at an increased risk of liver injury while using this medication. This caution relates to the fact that the medicine is processed by the liver.


Q: What types of food or supplements should be avoided when using Atractin?

Official prescribing information specifies certain substances with documented interaction risks. These include consuming large quantities of grapefruit or grapefruit juice and the herbal product St. John's Wort. Additionally, specific antacids containing magnesium and aluminum may reduce the absorption of the medicine.


Q: Can Atractin cause mood changes or unusual dreams?

The safety documentation for Atractin highlights the risk of psychiatric disorders as a clinically significant adverse reaction. This includes reported instances of depression, psychosis, and suicidal ideation, which are considered types of mood changes.


Q: How does Atractin interact with antacids or heartburn medicine?

Official documents list antacids containing magnesium and aluminum among products that interact with Atractin. This caution is included because these specific antacids may reduce the amount of the drug that the body absorbs.


Q: What should I expect in the first week of taking Atractin?

Official regulatory information does not detail a specific set of expectations for the first week of use. However, common adverse reactions, such as dry skin, back pain, or nosebleeds, may be reported early on. The medication's effectiveness is designed to be measured over a longer period, typically starting after at least four weeks of use.


Q: Does Atractin need to be taken at the exact same time every day?

Regulatory instructions state that the medicine is to be taken once daily and can be taken at any time of the day. Because the drug is long-acting, the specific time of day does not critically affect its efficacy. However, maintaining consistency in dosing time is associated with maintaining stable drug levels in the body.


Q: Does Atractin have a 'half-life' and what does that mean?

The term half-life refers to the time it takes for the concentration of the active substance in the body to be reduced by half. Official pharmacokinetic information for Atractin (Atorvastatin) reports an elimination half-life of approximately 14 hours.


Q: Does Atractin interact with common over-the-counter pain relievers like ibuprofen or aspirin?

The official interaction profile identifies certain categories of drugs that require mandatory warnings or dosage constraints. Regulatory documents list categories of medicines that require mandated warnings; common over-the-counter pain relievers such as ibuprofen or aspirin are not included in these specific, clinically significant interaction warnings.


Q: Is Atractin considered a controlled substance or habit-forming?

Regulatory agencies, such as the FDA, have not classified the active ingredient in Atractin, Atorvastatin, as a controlled substance. This classification indicates that it is not considered habit-forming.


Q: What happens if Atractin is taken during pregnancy?

Regulatory documents state that Atractin is contraindicated in pregnancy. The reason for this strict restriction is the cited extremely high risk of severe birth defects, also known as teratogenicity, during fetal development.


Q: Are there any ongoing clinical trials for Atractin that I can read about?

Information regarding clinical trials, including those currently running or recently completed, is registered on governmental databases. The National Institutes of Health (NIH) clinical trials registry tracks ongoing and completed research involving Atractin (Atorvastatin).


Q: Is it necessary to stop taking Atractin gradually, or can I stop all at once?

Official administration guidelines do not mandate a gradual discontinuation protocol for Atractin. However, discontinuation of any chronic cholesterol-lowering medication involves monitoring of lipid levels by a healthcare provider.


Q: What is the maximum dosage that has been studied in clinical trials?

The highest daily dosage listed in the official regulatory prescribing information for Atractin is 80 mg once daily. This is the maximum approved dose used in therapeutic studies.


Q: Is Atractin affected by cold or flu symptoms?

Official regulatory cautions advise that the medicine may be temporarily withheld during periods of acute, severe infection, which can include a major illness like a severe flu.


Q: Does Atractin affect the way my birth control pills work?

Official documentation explicitly lists Oral Contraceptives as a category of medicinal products with a documented interaction with Atractin. This information is included in the regulatory profile of the drug.


Q: What should I do if I notice a rash after starting Atractin?

Regulatory warnings highlight that serious skin reactions such as Stevens-Johnson syndrome (SJS) have been reported. A rash or other sudden skin changes are listed as potential signs of a serious adverse event that should be noted.


Q: Can Atractin be split or crushed if I have trouble swallowing pills?

Official administration guidelines specify that the film-coated tablet form of Atractin is intended to be swallowed whole. These instructions do not list any authorized methods for crushing or splitting the tablet.


Q: What are the signs of a possible allergic reaction to Atractin?

The medicine is strictly contraindicated for patients with a known hypersensitivity (allergy) to its ingredients. Regulatory safety documents also cite severe skin reactions, such as Stevens-Johnson syndrome, as key indicators of a serious adverse event or allergic response.


Q: Does Atractin interact with supplements like Vitamin D or Omega-3?

While official documents list specific herbal interactions (e.g., St. John's Wort), common daily supplements like Vitamin D or Omega-3 are generally not listed among those requiring mandated warnings or dosage constraints. These are not considered clinically significant interactions under regulatory guidelines.


Q: How is Atractin eliminated from the body?

Official pharmacokinetic information details how the body processes the medicine. This information indicates that the active substance and its metabolites are primarily eliminated from the body via biliary secretion (bile).


Q: Does the time of day I take Atractin matter for its effect?

Official prescribing information states the medicine may be taken at any time of the day. Because Atractin is a long-acting compound, its duration of action sustains its effect over a full 24-hour cycle, meaning the exact time of dosing does not impact its overall therapeutic effect.


Q: What are the long-term effects of taking Atractin for several years?

The long-term safety profile of Atractin includes specific warnings for the potential development of skeletal abnormalities. These reported issues include hyperostosis and the premature closure of growth plates in pediatric patients.


Q: Can I drive or operate heavy machinery while taking Atractin?

Official product information does not list a specific general restriction against driving or operating machinery. However, official information notes the possibility of adverse reactions, such as psychiatric disorders, that may affect concentration or reaction time.


Q: Is there a generic version of Atractin available?

The active ingredient in Atractin is Atorvastatin. Official regulatory records indicate that generic versions of this compound are available following patent expiration.


Q: Is Atractin a stimulant or a sedative?

Atractin is defined by its regulatory classification as a statin, belonging to the HMG-CoA reductase inhibitor class. Its general purpose is as a lipid-modifying agent, and it is not classified as a stimulant or a sedative.

How should Atractin be stored and disposed of?

Storage Conditions and Handling

Atractin must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The product must be protected from moisture to maintain its stability and should therefore not be stored in the bathroom.

To ensure proper protection, the medication must be kept in the original container and the container must remain tightly closed when not in use. As a mandatory safety requirement, Atractin must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Atractin must be disposed of according to official regulatory guidance. It is important to not dispose of this medication via wastewater (such as flushing down a toilet) or with regular household waste. Disposal should be carried out strictly according to local requirements for pharmaceutical products.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Atractin found in:

A-Z Index: